RET kinase inhibitor

orally efficacious in XG but narrow TI

from data mining of internal matter and opt.

ACS Med. Chem. Lett. Feb. 12, 2020

Novartis (GNF), San Diego, CA


(Novartis (GNF) oral in vivo RET kinase inhibitor)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: